CAF09 (Cationic Adjuvant Formulation 09) Datasheet DC Chemicals
Description
CAF09 (Cationic Adjuvant Formulation 09) is a novel liposome-based vaccine adjuvant system composed of the cationic liposome dimethyldioctadecylammonium bromide (DDA), the immunostimulant trehalose 6,6'-dibehenate (TDB), and the TLR3 agonist polyinosinic-polycytidylic acid (Poly(I:C )). This combination endows CAF09 with unique immunomodulatory properties, enabling it to simultaneously activate both innate and adaptive immune responses, particularly demonstrating remarkable efficacy in inducing robust Th1 and CD8+ T cell responses.
CAF09 enhances antigen uptake and presentation through its cationic liposome structure, while TDB activates C-type lectin receptors (such as Mincle) to amplify innate immune signaling. Additionally, Poly(I:C ) further strengthens immune activation via the TLR3 pathway. This multimodal immunostimulatory mechanism allows CAF09 to significantly enhance antigen immunogenicity and induce broad immune protection, encompassing both humoral and cellular immunity.
Research has shown that CAF09 holds great potential in the development of various vaccines, particularly for viral infections and cancer immunotherapy. Its potent immune-enhancing effects and favorable safety profile have been validated in preclinical studies, laying a solid foundation for its future application in human vaccine development. In summary, CAF09, as a highly effective and multifunctional adjuvant, provides robust technical support for the design and optimization of next-generation vaccines.
Cat.No
DC67251
Name
CAF09 (Cationic Adjuvant Formulation 09)
Chemical Properties
CAS
Formula
MW
Storage
2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
References
Return Policy
If you are in any way unsatisfied with your purchase, you may return any item(s) within 365 days of its original purchase date.
Please provide your Order Number in the email. We strive to reply to all email inquiries within one business day.
